Isocarboxazid
- Generic Name
- Isocarboxazid
- Brand Names
- Marplan
- Drug Type
- Small Molecule
- Chemical Formula
- C12H13N3O2
- CAS Number
- 59-63-2
- Unique Ingredient Identifier
- 34237V843T
- Background
Isocarboxazid has the formula 1-benzyl-2-(5-methyl-3-isoxazolylcarbonyl)hydrazine-isocarboxazid. It is a monoamine oxidase inhibitor. It is used in the treatment of major depression, dysthymic disorder, atypical disorder, panic disorder and the phobic disorders. It was first introduced by Roche pharmaceuticals, further developed by Validus pharms Inc and first FDA approved as a prescription drug on July 1st, 1959.
- Indication
Isocarboxazid is indicated for the treatment of the enduring and debilitating symptoms of depression that have not responded to other antidepressant drugs. Depression is a common but serious mood disorder. The patient will present changes in its feelings, thoughts, and ability to handle everyday activities. For a mood disorder to be considered as depression, the symptoms should be present for at least two weeks.
- Associated Conditions
- Depression
- Associated Therapies
- -
I2PETHV - Imidazoline2 Binding Site in Healthy Volunteers
- Conditions
- Healthy VolunteersAlzheimer DiseaseMolecular Imaging
- Interventions
- First Posted Date
- 2014-12-23
- Last Posted Date
- 2021-11-15
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 20
- Registration Number
- NCT02323217
- Locations
- 🇬🇧
Centre for Neuropsychopharmacology; Division of Brain Sciences; Imperial College London; Burlington Danes Building; Hammersmith Hospital campus; 160 Du Cane Road, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.